ストックスクリーナーアプリを入手
75.83
1.03%
1.0152
Cytokinetics Inc (CYTK) 最新ニュース
1CYTK.MI Stock Price, Quote & Chart | CYTOKINETICS INC (BIT:1CYTK) - ChartMill
J.P. Morgan Maintains Cytokinetics(CYTK.US) With Buy Rating, Raises Target Price to $97 - Moomoo
Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference - The Manila Times
CYTK Maintained by JP Morgan -- Price Target Raised to $97.00 - GuruFocus
Growth Investors: Industry Analysts Just Upgraded Their Cytokinetics, Incorporated (NASDAQ:CYTK) Revenue Forecasts By 11% - Yahoo Finance
Analysts Are Betting On Cytokinetics, Incorporated (NASDAQ:CYTK) With A Big Upgrade This Week - 富途牛牛
Cytokinetics (CYTK) Unveils Positive MYQORZO Data at ESC 2026 Co - GuruFocus
One Bay Area company scored $800 million around its heart drug. Here's another targeting the same condition - The Business Journals
Cytokinetics completes $805 million public offering - The Pharma Letter
Cytokinetics presents new data on heart drug aficamten - Investing.com
Cytokinetics presents new data on heart drug aficamten By Investing.com - Investing.com India
Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 - Caledonian Record
Heart drug MYQORZO shows long-term safety as HCM burden detailed - Stock Titan
CYTK Maintains by HC Wainwright & Co. -- Price Target Raised to $140 - GuruFocus
1CYTK.MI Stock Chart | CYTOKINETICS INC (BIT:1CYTK) - ChartMill
Can Myqorzo drive growth for Cytokinetics amid competition? - MSN
Cytokinetics (NASDAQ: CYTK) prices $760.2M common stock sale at $71 - Stock Titan
Cytokinetics closes $805 million stock offering By Investing.com - Investing.com South Africa
Cytokinetics closes $805 million stock offering - Investing.com
$805M raised as Cytokinetics sells 11.3M shares at $71 each - Stock Titan
Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $805 Million - marketscreener.com
CYTK SEC FilingsCytokinetics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Earnings Update: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Are Boosting Their Estimates - Moomoo
CYTK Maintained by Wells Fargo -- Price Target Raised to $105 - GuruFocus
Cytokinetics, Incorporated 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CYTK) 2026-05-07 - Seeking Alpha
Cytokinetics: Expect Gross Proceeds of Around $700M >CYTK - Moomoo
Cytokinetics (NASDAQ: CYTK) prices 9.859M-share offering to raise $700M - Stock Titan
B. Riley Adjusts Price Target on Cytokinetics to $146 From $108, Maintains Buy Rating - Moomoo
Jefferies raises Cytokinetics stock price target on trial results - Investing.com UK
Jefferies raises Cytokinetics stock price target on trial results By Investing.com - Investing.com Australia
Cytokinetics Is Maintained at Overweight by Wells Fargo - Moomoo
Earnings Beat: Cytokinetics, Incorporated (NASDAQ:CYTK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - Yahoo Finance
Cytokinetics Price Target Raised to $108.00/Share From $98.00 by Stifel - Moomoo
Why is Cytokinetics (CYTK) down 0.8% since last earnings report? - MSN
Cytokinetics Prices Upsized $700 Million Share Offering - marketscreener.com
Cytokinetics prices upsized $700M equity raise at $71 per share - MSN
Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock - The Manila Times
Cytokinetics prices $700 million stock offering at $71 per share By Investing.com - Investing.com Australia
Cytokinetics prices $700 million stock offering at $71 per share - Investing.com
Cytokinetics Announces Pricing of $700 Million Public Offering of Common Stock - Quiver Quantitative
Cytokinetics prices public offering of 9.8 mln shares at $71/share - marketscreener.com
Cytokinetics prices nearly 9.9M-share sale at $71 a share - Stock Titan
Cytokinetics Offering Expected to Close May 8 >CYTK - Moomoo
CYTK Q1 Earnings Match Estimates, Revenues Beat on Myqorzo Launch - TradingView
RBC Adds Speculative Risk to Outperform Rating on Cytokinetics, Lifts Price Target to $119 From $101 - Moomoo
A Quick Look at Today's Ratings for Cytokinetics(CYTK.US), With a Forecast Between $101 to $136 - Moomoo
Cytokinetics' Rapid Growth of Myqorzo not Fully Priced in by Investors, RBC Says - marketscreener.com
Cytokinetics rallies on late-stage Myqorzo data, strengthening sales outlook - S&P Global
FMR LLC increases stake in Cytokinetics (NASDAQ: CYTK) to 9.0% - Stock Titan
Truist raises Cytokinetics stock price target on positive trial data By Investing.com - Investing.com South Africa
Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints - Sahm
Truist raises Cytokinetics stock price target on positive trial data - Investing.com
Fresh off big clinical trial win, Cytokinetics looks to raise about $650 million - The Business Journals
Cytokinetics Inc : B. Riley Raises Target Pri - Moomoo
0.48%
0.62%
大文字化:
|
ボリューム (24 時間):